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ABSTRACT
Background and Aims Coffee consumption and cigarette smoking are strongly associated, but whether this association
is causal remains unclear. We sought to: (1) determine whether coffee consumption inﬂuences cigarette smoking causally,
(2) estimate the magnitude of any association and (3) explore potential mechanisms. Design We used Mendelian
randomization (MR) analyses of observational data, using publicly available summarized data from the Tobacco and
Genetics (TAG) consortium, individual-level data from the UK Biobank and in-vitro experiments of candidate compounds.
Setting The TAG consortium includes data from studies in several countries. The UK Biobank includes data from men
and women recruited across England, Wales and Scotland. Participants The TAG consortium provided data on
n ≤ 38181 participants. The UK Biobank provided data on 8072 participants. Measurements In MR analyses, the
exposure was coffee consumption (cups/day) and the outcome was heaviness of smoking (cigarettes/day). In our in-vitro
experiments we assessed the effect of caffeic acid, quercetin and p-coumaric acid on the rate of nicotine metabolism in
human liver microsomes and cDNA-expressed human CYP2A6. Findings Two-sample MR analyses of TAG consortium
data indicated that heavier coffee consumption might lead to reduced heaviness of smoking [beta = 1.49, 95%
conﬁdence interval (CI) = 2.88 to 0.09]. However, in-vitro experiments found that the compounds investigated are
unlikely to inhibit signiﬁcantly the rate of nicotine metabolism following coffee consumption. Further MR analyses in
UKBiobank foundno evidence of a causal relationship between coffee consumption andheaviness of smoking (beta =0.20,
95% CI = –1.72 to 2.12). Conclusions Amount of coffee consumption is unlikely to have a major causal impact upon
amount of cigarette smoking. If it does inﬂuence smoking, this is not likely to operate via effects of caffeic acid, quercetin or
p-coumaric acid on nicotine metabolism. The observational association between coffee consumption and cigarette
smoking may be due to smoking impacting on coffee consumption or confounding.
Keywords Causal inference, coffee, cigarette smoking, CYP2A6 metabolism, smoking heaviness, Mendelian
randomisation.
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INTRODUCTION
Coffee consumption is associated with smoking [1–3].
Observational studies show that coffee drinkers are
more likely to be smokers than non-consumers [2,3]
and smoke more heavily [1]. This may arise via a
number of possible mechanisms—constituents of coffee
may have a pharmacological impact on the actions
or metabolism of nicotine, or conditioning processes
may lead to learned associations between the
consumption of one and the other [1]. Given the
widespread use of coffee world-wide, and the
substantial health burden posed by cigarette smoking,
determining the potential causal impact of coffee
consumption on smoking behaviour is of clear public
health importance. However, traditional observational
epidemiological studies cannot determine direction of
causality conﬁdently, and cannot rule out the
possibility of confounding by an unmeasured (or poorly
measured) variable.
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Mendelian randomization (MR) is a method which can
be applied to observational data in order to: (a) provide
evidence for the existence of causal relationships between
variables and (b) estimate the magnitude of these
relationships [4]. It uses genetic variants that have been
shown to be associated robustly with an exposure (e.g.
coffee consumption) as proxies for the exposure. MR relies
on the basic (but approximate) laws of Mendelian genetics:
segregation and independent assortment. If these two laws
hold, then, at a population level, genetic variants will not
be associated with the confounding factors that can distort
conventional observational studies. Furthermore, the
gene variants with which individuals are born should
not be altered by environmental factors, such as the
outcome of interest, which removes the issue of reverse
causality. This approach has been used to examine the
causal impact of cigarette smoking on a variety of health
outcomes [5–7]. The identiﬁcation of genetic variants
associated with coffee consumption [8–12] presents the
opportunity to use MR to examine the causal impact of
coffee consumption on smoking.
Using conventional MR, the existence and magnitude
of causal associations between an exposure and an
outcome are determined by assessing the gene–exposure
and gene–outcome relationships in the same data set or
sample, where data on the genetic variant, exposure and
outcome are available for all participants (i.e. one-sample
MR). However, it is also possible to use two independent
data sets or samples to assess each of these relationships,
one of which includes data on genotype and the exposure,
and the other on genotype and the outcome. This
approach is known as two-sample MR [13], and is useful
when it is hard to ﬁnd study populations with data on
the required genetic variant(s), exposure and outcome,
particularly those of an adequate size for MR analyses
(which typically require sample sizes in the 10s of
1000s). The two-sample approach can also be applied to
publicly available summary data from large-scale genetic
association studies [14]. Here we applied a two-sample
MR approach, using publicly available data, to explore
the existence of a causal effect of coffee consumption on
smoking heaviness, and followed this up with in-vitro
experiments and replication in UK Biobank. We sought
to: (1) determine whether coffee consumption causally
inﬂuences cigarette smoking, (2) estimate the magnitude
of any association and (3) explore potential mechanisms.
STUDY 1
Design
We performed two-sample MR analyses, in which evidence
for gene–exposure and gene–outcome associations were
taken from different sources, using publicly available
summarized data, in order to determine whether coffee
consumption causally inﬂuences cigarette smoking, and
estimate the magnitude of any association. This
approach has been described elsewhere by Burgess and
colleagues [14].
Methods
We used summary-level data from the European
replication sample Coffee and Caffeine Genetics
Consortium (CCGC) (N ≤ 30062) for the gene–exposure
association. The phenotype in this genome-wide
association study (GWAS) was cups of coffee consumed
per day among consumers. Estimates for the associations
of SNPs with coffee consumption were taken from analyses
restricted to individuals of European ancestry. Full details of
how this coffee consumption was assessed and control for
population stratiﬁcation in each contributing cohort are
available in the supplementary material of the GWAS
publication [8]. Gene outcome associations were obtained
from summary level data from the Tobacco and Genetics
(TAG) consortium (cigarettes per day phenotype,
n ≤ 38181) and the cotinine consortium for the gene–
outcome associations (n ≤ 4548) (see Supporting
information).
Three speciﬁc combinations of single nucleotide
polymorphisms (SNPs) that capture coffee consumption
were used, corresponding to three models: (1) a set of eight
independent (r2 < 0.0006) SNPs (rs1260326,
rs1481012, rs4410790, rs7800944, rs17685, rs6265,
rs2470893, rs9902453), comprising variants which met
the threshold for genome-wide signiﬁcance (log10 Bayes
factor > 5.64) in the trans-ethnic GWAS meta-analysis of
coffee consumption reported by the CCGC; (2) a moderate
set of six SNPs (rs1260326, rs4410790, rs7800944,
rs17685, rs2470893, rs9902453), which limited the full
set to those variants which met the threshold of P < 0.05
in the CCGC stage 2 European sample GWAS; and (3) a
conservative set of two SNPs (rs4410790, rs2470893),
which limited the full set to variants in loci also identiﬁed
in previous GWAS, in or near genes with a biological role
in caffeine metabolism [8–12]. The gene–exposure and
gene–outcome associations were identiﬁed in the CCGC
[8], TAG [15] and cotinine [16] consortia summary-level
data. Models 2 and 3 were included as sensitivity analyses,
as recommended by Burgess and colleagues [14]. These
used variants with stronger evidence for association with
coffee consumption (model 2) and those with the most
speciﬁc phenotypical impact (model 3), enabling us to
assess the possibility that our primary results (model 1)
were attributable to genetic pleiotrophy (Table 1).
The causal change in smoking heaviness per unit
increase in coffee consumption (i.e. per additional cup of
coffee consumed per day) was estimated using the Wald
2 Jennifer J. Ware et al.
© 2017 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
ratio, with standard errors approximated by the delta
method [17,18]. The SNP score is weighted according to
associations with coffee consumption (measured as cups
per day) in the CCGC GWAS (e.g. an allele which increases
coffee consumption by 0.1 cups per day is given a value of
0.1). Therefore, the association with the outcome measure
is expressed as the difference in outcome per additional cup
of coffee consumed per day. Wald ratios were estimated for
each SNP separately and combined by ﬁxed-effects meta-
analysis. This statistical approach has been described in full
elsewhere [14]. We also conducted a sensitivity analysis
using the weighted median function approach [19]. This
approach is a way to test further the validity of a multi-
SNP instrument, as it generates a consistent estimate of
causal effect even when up to 50% of the information in
the analysis comes from SNPs that are invalid (e.g. subject
to pleiotrophy). It therefore provides a simple means of
assessing the robustness of the standard MR analysis to
violations of MR assumptions (e.g. pleiotropy). All 95%
CIs were calculated as 1.96 x SE. All statistical analyses
were conducted using the R statistical software package
(x64 version 3.0.1). Figures were generated using Stata
version 11.
Results
Smoking heaviness (cigarettes per day)
There was evidence in support of a causal effect of coffee
consumption on smoking heaviness. Each additional
cup of coffee consumed per day corresponded to a
decrease in daily cigarette consumption of approximately
1.5 cigarettes per day within a ﬁxed-effects framework
(eight-SNP model: beta = 1.49, 95% CI = –2.88 to
0.09, P = 0.037; six-SNP model: beta = 1.69, 95%
CI = –3.13 to 0.24, P = 0.022; two-SNP model:
beta = 2.09, 95% CI = –3.94 to 0.24, P = 0.027)
(Table 1, Fig. 1). The weighted median function approach
using all eight SNPs also generated a similar estimate
(beta = 2.15, 95% CI = –3.73 to 0.07).
Smoking heaviness (cotinine levels)
There was no clear evidence in support of a causal effect of
coffee consumption on cotinine levels, although the
direction of effect was consistent with that observed for
daily cigarette consumption (i.e. a negative effect size
estimate was observed) (eight-SNP model: beta = 0.26,
95% CI = –0.62 to 0.10, P = 0.16; six-SNP model:
beta = 0.29, 95% CI = –0.66 to 0.09, P = 0.13; two-
SNP model: beta = 0.38, 95% CI = –0.88 to 0.12,
P= 0.14) (Table 2, Fig. 2). Beta values refer to the standard
deviation (SD) change in cotinine levels per cup of coffee
consumed per day. For reference, a 0.26 SD decrease in
cotinine level corresponds to ~46 ng/ml decrease in
plasma/serum cotinine.
Discussion
These results suggested that coffee consumption may
reduce heaviness of smoking, in contrast to evidence from
observational studies. Cigarette consumption can decrease
without cotinine levels being altered (e.g. if fewer cigarettes
are smoked more intensively), so our results for cigarettes
per day and cotinine are not necessarily inconsistent.
Inhibition of CYP2A6-mediated nicotine metabolism by
constituents of coffee prolongs nicotine’s clearance may
be similar to the established impact of reduced nicotine
metabolizer phenotype on reducing smoking in these
smoking coffee consumers [20]. It is known that smoking
induces the enzyme cytochrome P450 1A2 (CYP1A2)
Table 1 Coffee consumption and smoking heaviness (cigarettes per day).
SNP Gene
Model inclusions
Effect
allele
Other
allele
Association with coffee
(cups per day)a
Association with smoking
(cigarettes per day)b
Beta
Standard
error Beta
Standard
error8-SNP 6-SNP 2-SNP
rs1260326 GCKR Yes Yes No C T 0.03 0.01 0.0821 0.0826
rs1481012 ABCG2 Yes No No A G 0.03 0.02 0.0297 0.1355
rs4410790 AHR Yes Yes Yes C T 0.05 0.01 0.0679 0.0906
rs7800944 MLXIPL Yes Yes No C T 0.06 0.02 0.0881 0.0973
rs17685 POR Yes Yes No A G 0.05 0.01 0.1387 0.1377
rs6265 BDNF Yes No No C T 0.03 0.01 0.0465 0.1045
rs2470893 CYP1A1 Yes Yes Yes T C 0.09 0.01 0.2125 0.0964
rs9902453 EFCAB5 Yes Yes No G A 0.03 0.01 0.0642 0.0817
For all three models, linkage disequilibrium (LD) pruning was performed: where pairs of variants were in LD, one of the variants was removed at random,
ensuring total independence of all single nucleotide polymorphisms (SNPs) included in each model (r
2
< 0.0006 in all instances). The rs6968554 SNP, used
in the 2 SNPmodel, was not included in the full 8 SNPmodel due to high LDwith rs4410790 (r
2
= 0.99). aBetas and standard errors from replication sample
of Coffee and Caffeine Genetics Consortium (CCGC) genome-wide association study (GWAS) meta-analysis, n ≤ 30 062. bBetas and standard errors from
discovery sample of Tobacco and Genetics (TAG) GWAS meta-analysis, n ≤ 38 181.
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(the main enzyme involved in caffeine metabolism), and
therefore increases metabolism of caffeine [21,22]. It is also
possible that constituents of coffee may have a
pharmacological impact on the actions or metabolism of
nicotine [1]. Previous in-vitro research has shown that
caffeic acid and quercetin, compounds present in coffee,
unrelated to caffeine, inhibit bovine cytochrome P450
2A6 (CYP2A6) enzyme activity [23]. CYP2A6 plays a
major role in nicotine metabolism, and is responsible for
~80% of the inactivation of nicotine to cotinine [24]. A
reduction in nicotine metabolism via inhibition of CYP2A6
activity would result in longer-lasting circulating levels of
nicotine per unit intake, thus extending its window of
pharmacological effect and leading to a reduction in
smoking. Previous human experimental studies have
focused on manipulation of caffeine dose, rather than
coffee dose, and show little or no evidence of a relationship
between caffeine dose and cigarette consumption [25,26],
but this is not inconsistent with the mechanism we
propose.
Figure 1 Coffee consumption and smoking heaviness forest plot (cigarettes per day). Effect size (ES) estimates reﬂect change in daily cigarette
consumption per additional cup of coffee consumed per day. CI = conﬁdence interval; CPD = cigarettes per day; SNP = single nucleotide
polymorphism [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
Table 2 Coffee consumption and smoking heaviness (cotinine).
SNP Gene
Model inclusions
Effect
allele
Other
allele
Association with coffee
(cups per day)a
Association with
smoking (cotinine)b
Beta
Standard
error Beta
Standard
error8-SNP 6-SNP 2-SNP
rs1260326 GCKR Yes Yes No C T 0.03 0.01 0.0102 0.0207
rs1481012 ABCG2 Yes No No A G 0.03 0.02 0.0139 0.0323
rs4410790 AHR Yes Yes Yes C T 0.05 0.01 0.0087 0.0208
rs7800944 MLXIPL Yes Yes No C T 0.06 0.02 0.0114 0.0284
rs17685 POR Yes Yes No A G 0.05 0.01 0.0319 0.0258
rs6265 BDNF Yes No No C T 0.03 0.01 0.0163 0.0262
rs2470893 CYP1A1 Yes Yes Yes T C 0.09 0.01 0.0647 0.0284
rs9902453 EFCAB5 Yes Yes No G A 0.03 0.01 0.0002 0.0204
For all three models, linkage disequilibrium (LD) pruning was performed: where pairs of variants were in LD, one of the variants was removed at random,
ensuring total independence of all single nucleotide polymorphisms (SNPs) included in each model (r
2
< 0.0006 in all instances). The rs6968554 SNP, used
in the 2 SNPmodel, was not included in the full 8 SNPmodel due to high LDwith rs4410790 (r
2
= 0.99). aBetas and standard errors from replication sample
of Coffee and Caffeine Genetics Consortium (CCGC) genome-wide association study (GWAS) meta-analysis, n ≤ 30 062. bBetas and standard errors from
discovery sample of cotinine GWAS meta-analysis, n ≤ 4548.
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It is important to note that the most strongly
associated coffee-related SNPs identiﬁed to date (in or
near AHR and CYP1A2) increase coffee consumption
by increasing caffeine metabolism, leading to a decrease
in circulating caffeine levels. This has been shown in a
GWAS of blood metabolites and of caffeine metabolites
[27,28]. Caffeine is metabolized primarily by the enzyme
CYP1A2 [29], but does not inhibit nicotine phar-
macokinetics in-vivo nor does it alter cigarette
consumption [25,30]. For example, when given caffeine
at a high dose (12 mg/kg/day, approximately 800 mg
per person, relative to average daily consumption of
200 mg) there was no effect on nicotine or cotinine
plasma levels or on nicotine intake, cigarettes smoked
or grams of tobacco burned [23]; therefore, caffeine
was not investigated further as a potential CYP2A6
inhibitor. Instead we explored the inhibitory potential of
three alternative compounds present in coffee, caffeic
acid, quercetin and p-coumaric acid on human nicotine
metabolism [31]. In contrast, caffeic acid and quercetin
reduce the rate of metabolism of the CYP2A6 substrate,
coumarin, in bovine liver microsomes and were thus
investigated as potential inhibitors of human nicotine
metabolism [23].
STUDY 2
Design
Using 8-methoxypsoralen as a positive inhibitory control
[32], we assessed the effect of caffeic acid, quercetin and
p-coumaric acid on the rate of nicotine metabolism in
human liver microsomes and cDNA-expressed human
CYP2A6 in order to explore potential mechanisms for the
results observed in study 1.
Methods
()-Nicotine hydrogen tartrate, ()-cotinine, caffeic acid,
quercetin, p-coumaric acid and 8-methoxypsoralen were
purchased from Sigma-Aldrich (St Louis, MO, USA).
CYP2A6 supersomes were purchased from BD Gentest
(Woburn, MA, USA). The custom-made internal
standard, 5-methylcotinine, was purchased from Toronto
Research Chemicals (Toronto, ON, Canada). Human liver
microsome preparation and in-vitro inhibition of nicotine
metabolism were performed as described previously
[32,33]; further details can be found in the Supporting
information. The inhibitory potency of each inhibitory
test compound was determined by incubating human
liver microsomes or CYP2A6 supersomes with nicotine
and various concentrations of each compound under
linear conditions for nicotine metabolism. Positive control
experiments were also conducted using the established
CYP2A6 inhibitor 8-methoxypsoralen [32]. We assessed
the velocity of cotinine formation (V, nmol/mg
protein/min for microsomes, nmol/pmol CYP2A6/min
for supersomes) and the inhibitor constant (Ki) for each
test compound; Ki values were estimated using Dixon
plots, while Cornish–Bowden plots were used to infer
the type of inhibition (competitive, non-competitive,
uncompetitive or mixed). The relative impact of inhibitor
pre-incubation versus no pre-incubation on the rate of
cotinine formation was used to investigate whether or
Figure 2 Coffee consumption and smoking heaviness forest plot (cotinine). Effect size (ES) estimates reﬂect standard deviation change in cotinine
levels per additional cup of coffee consumed per day. CI = conﬁdence interval [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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not the compounds had the potential to act as
irreversible inhibitors. Analyses were performed using
GraphPad Prism version 6.0.
Results
Inhibition of in-vitro nicotine metabolism by caffeic acid,
quercetin and p-coumaric acid
All three test coffee compounds inhibited CYP2A6 activity,
reducing the rate of cotinine formation from nicotine. In
human liver microsomes and CYP2A6 supersomes
quercetin (Fig. 3) had the lowest inhibitory constant
(lowest Ki), and thus the highest afﬁnity and greatest
inhibition against cotinine formation (microsomes
19 μM, supersomes 21 μM), followed by caffeic acid
(microsomes 152 μM, supersomes 156 μM) and
p-coumaric acid (microsomes 247 μM, supersomes
243 μM) (Supporting information, Figs S1, S2a,b). All
three compounds exhibited substantially lowered inhibitor
potency compared to our positive control,
Figure 3 Inhibition of cytochrome P450 2A6 (CYP2A6) activity by quercetin. Dixon plots of the inhibition of nicotine metabolism by CYP2A6 in
the presence of increasing concentrations of quercetin in (a) human CYP2A6 supersomes and (b) human liver microsomes (without pre-incubation).
Cornish–Bowden plots of nicotine (μM)/velocity (nmol/min/mg) with increasing concentrations of quercetin in (c) human CYP2A6 supersomes and
(d) human liver microsomes (without pre-incubation). Comparison of CYP2A6 inhibition by quercetin with and without pre-incubation, at increasing
inhibitor concentrations in (e) human CYP2A6 supersomes and (f) human liver microsomes. Velocity (V), supersomes: nmol cotinine/min/pmol
CYP2A6, microsomes: nmol cotinine/min/mg [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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8-methoxypsoralen (microsomes 0.18 μM, supersomes
0.20 μM; Supporting information, Fig. S3a,b). Caffeic acid
and p-coumaric acid demonstrated characteristics of
competitive inhibitors (Supporting information, Figs S1,
S2c,d), while quercetin appeared to act as amixed inhibitor
(Fig. 3c,d). 8-Methoxypsoralen, an established in-vitro
mechanism-based inhibitor for CYP2A6, showed the
expected mixed inhibition [34], which is typical for these
in-vitro tests for a mechanism-based inhibitor. The Ki and
type of inhibition for each compound has been summarized
in Supporting information, Table S2.
Effect of pre-incubation with inhibitor on in-vitro nicotine
metabolism
We pre-incubated human liver microsomes and CYP2A6
supersomes with each inhibitor prior to administration of
nicotine to assess if they might act as irreversible
inhibitors. Mechanism-based inhibition is such that the
compound is activated metabolically by the enzyme,
and subsequently the product binds irreversibly [35];
we would expect to observe increased inhibition of
cotinine formation with inhibitor pre-treatment relative
to standard inhibitor treatment for a mechanism-based
inhibitor. There was no difference in the percentage of
CYP2A6 activity (cotinine formation from nicotine)
remaining after treatment with increasing con-
centrations of the test compounds (caffeic acid, quercetin
and p-coumaric acid) between the inhibitor pre-
treatment and non-pre-treatment conditions (Fig. 3,
Supporting information, Figs S1, S2e,f), suggesting that
these compounds do not act as irreversible inhibitors.
Pre-treatment with 8-methoxypsoralen was associated
with a greater decrease in the percentage of CYP2A6
activity remaining relative to the non-pre-treatment
group (Supporting information, Figure S3e,f),
consistent with its known function as an in-vitro
mechanism-based inhibitor of CYP2A6 [34].
Discussion
Our results indicated that three test compounds present in
coffee—caffeic acid, quercetin and p-coumaric acid—each
act as inhibitors of cotinine formation from nicotine. The
test inhibitors are present at low amounts in coffee;
therefore, to be capable of inhibiting nicotine metabolism
sufﬁciently enough to reduce smoking, they would have
to be either (1) very potent or (2) a mechanism-based-
inhibitor. The potency of inhibition varied between each
compound, and was several magnitudes lower than that
of 8-methoxypsoralen, our positive inhibitory control. The
type of inhibition also differed between compounds.
Competitive inhibition, which was demonstrated by caffeic
acid and p-coumaric acid towards cotinine formation, is
characterized by reversible binding of the inhibitor to the
substrate-binding site, with the potential for this inhibition
to be overcome by high concentrations of the substrate (i.e.
nicotine) [36]. Quercetin exhibited characteristics of a
mixed inhibitor, suggesting that this compound binds to
the vacant, or already substrate-bound, enzyme with
greater afﬁnity for one state or the other [37].
8-Methoxypsoralen was the only compound to act as a
mechanism-based inhibitor, in agreement with the
literature [34]. 8-Methoxypsoralen inhibits nicotine
metabolism in-vitro and in-vivo signiﬁcantly and decreases
smoking, and therefore was a suitable positive control for
this study [38,39].
Based on these ﬁndings, we can predict roughlywhether
the amount of each compound present in one cup of coffee
is adequate to substantially inhibit nicotine metabolism and
reduce smoking. The amount of total caffeic acid, quercetin
and p-coumaric acid per cup of coffee is between 6 and
175 mg, 0.005 mg and 0.14 mg, respectively [40–42].
Considering the relatively low quantities of quercetin and
p-coumaric acid present in coffee, and the inhibitory
potencies of both compounds, it is unlikely that either
compound is responsible for substantial inhibition of
nicotine metabolism following coffee consumption.
However, caffeic acid intake from coffee is much higher,
due probably to the presence of free caffeic acid in coffee
and the formation of caffeic acid in the body as a metabolic
product of chlorogenic acid, which is found at amounts
ranging from 10 to 350 mg per cup of coffee [41–44].
Caffeic acid and caffeine are actually present at similar
amounts in coffee, with one cup of coffee containing
approximately 100 mg of each compound [41]. The
average plasma levels of caffeine among smokers has been
assessed after consumption of increasing amounts of coffee
[45], and we can use these data to roughly estimate caffeic
acid plasma concentrations (see Supporting information). A
plasma caffeic acid concentration of 1.11 mg/l (6.16 μM),
corresponding to a consumption of two to three cups of
coffee, would result in 3.8% greater inhibition of nicotine
metabolism relative to no caffeic acid. When smokers
consume three to four cups of coffee per day, their
plasma caffeic acid concentration is predicted to be
1.28 mg/l (7.12 μM), resulting in a 4.4% inhibition of
nicotine metabolism. With each additional cup of coffee
consumed, the inhibition of nicotine metabolism increases
by < 1%. Based on the shorter half-life and lower levels
of caffeic acid compared to caffeine, our assumptions
overestimate the potential effects of caffeic acid; based
on these over-assumptions, there was still little support
that caffeic acid from coffee consumption was probably
able to inhibit nicotine metabolism sufﬁciently to result
in a decrease of 1.5 cigarettes per day with the
consumption of each additional cup of coffee.
Our ﬁndings therefore suggest that caffeic acid,
quercetin and p-coumaric acid inhibit CYP2A6 enzymatic
Coffee and smoking 7
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activity, but with relatively low inhibitory potency. This,
along with the amount of each compound present in
coffee, suggests that these compounds do not inhibit the
rate of nicotine metabolism following coffee consumption
substantially, and that these coffee constituents are
unlikely explanations for the ﬁndings in study 1. We
therefore explored whether the results of study 1 could be
replicated in a large cohort study, the UK Biobank.
STUDY 3
Design
We performed MR analyses using individual data from the
UK Biobank study, in order to replicate the ﬁndings rom
study 1.
Methods
The UK Biobank (www.ukbiobank.ac.uk) recruited more
than 500000 men and women (aged 37–73 years)
between 2006 and 2010 [46]. Participants attended one
of the 21 assessment centres in England, Wales and
Scotland, where they provided information on
demographic, life-style factors andmedical history through
interviews and questionnaires and had physical
measurements and blood, urine and saliva samples taken.
The full protocol for the study is available online: www.ukb
iobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-
Protocol.pdf. The UK Biobank study was approved by the
North West Multi-Centre Research Ethics Committee and
all participants provided written informed consent to
participate in the UK Biobank study.
Genotyping of the eight coffee-related variants
(rs4410790, rs2470893, rs1260326, rs1481012,
rs7800944, rs9902453, rs17685, rs6265) was conducted
in an initial sample of 152249 individuals. Full details of
the genotyping are provided in Supporting information.
The analysis sample was restricted to unrelated individuals,
based on a threshold of 0.05 estimated from genetic
kinships, and to individuals of European genetic ancestry
using principal components analyses (PCA). This resulted
in a sample of 114963 with genetic data. Two weighted
genetic risk scores were calculated; one using all eight SNPs
and the other using just the SNPs in AHR and CYP1A1
(rs4410790 and rs2470893). SNPs were weighted using
beta coefﬁcients from the replication stage of the CCGC
GWAS (Supporting information, Table S3).
Individuals were asked: ‘How many cups of coffee do
you drink each day?’. Answers were provided on a
continuous scale. For the purposes of this analysis, no
distinction was made between caffeinated and
decaffeinated coffee consumption. Current regular
smokers were asked about number of cigarettes consumed
per day; answers were provided on a continuous scale.
Analyses were conducted in Stata version 14 and R
version 3.0.1. The analysis sample was restricted to
current daily smokers, who reported consuming at least
some coffee. We assessed observational associations
between coffee consumption and daily cigarette
consumption using linear regression. To assess the validity
of the instrument, we tested the association between
genetic risk scores for coffee consumption and self-reported
coffee consumption and a range of possible confounders
(age, sex, income, educational attainment, deprivation
index). We conducted the Mendelian randomization
analysis in the same way as the two-sample analysis, by
calculating Wald ratios for each SNP separately and
combining using inverse variance weighted ﬁxed-effects
meta-analysis. We also performed a median weighted
regression as a sensitivity analysis [19]. Regressions were
adjusted for age, sex and the 15 principal genetic
components provided by UK Biobank. Robust standard
Table 3 Coffee consumption and smoking heaviness (cigarettes per day) in UK Biobank.
SNP Gene
Model inclusions
Effect
allele
Other
allele
Association with coffee
(cups per day)a
Association with smoking
(cigarettes per day)b
Beta
Standard
error Beta
Standard
error8-SNP 2-SNP
rs1260326 GCKR Yes No C T 0.03 0.01 0.214 0.132
rs1481012 ABCG2 Yes No A G 0.03 0.02 0.203 0.202
rs4410790 AHR Yes Yes C T 0.05 0.01 0.016 0.128
rs7800944 MLXIPL Yes No C T 0.06 0.02 0.006 0.140
rs17685 POR Yes No A G 0.05 0.01 0.015 0.137
rs6265 BDNF Yes No C T 0.03 0.01 0.207 0.167
rs2470893 CYP1A1 Yes Yes T C 0.09 0.01 0.076 0.135
rs9902453 EFCAB5 Yes No G A 0.03 0.01 0.144 0.125
aBetas and standard errors from replication sample of CCGC genome-wide association study (GWAS) meta-analysis, n ≤ 30 062. bBetas and standard errors
from UK Biobank, n = 8072. SNP = single nucleotide polymorphism.
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errors were used to account for non-normality of residuals.
All 95% CIs were calculated as 1.96 x SE.
Results
Characteristics of the study sample are shown in
Supporting information, Table S4. Median coffee
consumption was three cups per day [interquartile range
(IQR) = 2–5] and median cigarette consumption was 15
cigarettes per day (IQR = 15–20). Among the 8072
current daily smokers who reported consuming coffee,
each additional cup of coffee consumed per day was
associated with smoking 0.45 additional cigarettes per
day (95% CI = 0.39–0.52). Both the eight-SNP and two-
SNP genetic risk scores for coffee were associated with
coffee consumption; however, only the eight-SNP genetic
risk score had an F-statistic > 10 (F = 20.8), indicating
that it was likely to be a sufﬁciently strong instrument for
the analysis. Therefore, only the results using the eight-
SNP score are presented here. The average effects per coffee
consumption increasing allele were 0.08 additional cups
per day (95% CI = 0.04–0.11) for the eight-SNP score.
Neither the eight-SNP nor the two-SNP scores were
associated with potential confounders (Supporting
information, Table S4).
The associations of the coffee-related SNPs with
cigarette consumption in UK Biobank are shown in
Table 3. When Wald ratios were combined in a ﬁxed-
effects meta-analysis, there was no clear evidence for a
causal effect of coffee consumption on daily cigarette
consumption (beta per additional cup of coffee
consumed= 0.20 additional cigarettes per day, 95%CI = –
1.72 to 2.12, P = 0.84) using the eight-SNP score (Fig. 4).
This was consistent with the estimate from median
weighted regression (0.38, 95% CI = –1.83 to 2.59,
P = 0.74). As the ﬁrst release of UK Biobank GWAS data
includes a case–control study which selected individuals
on the basis of lung function (high, medium and low)
and smoking status (never smoking and heavy smoking)
(the UK Bileve study [47]), we also repeated this analysis
excluding these individuals (n = 4751) and results were
similar (data not shown).
Discussion
These results failed to support the observation in study 1,
that consumption may reduce heaviness of smoking.
Indeed, the point estimates were in the direction of an
increase in heaviness of smoking. This, together with the
results of study 2, suggests that coffee consumption does
not causally decrease heaviness of smoking. Some caution
must be exercised, as the conﬁdence intervals were wide
and included effects that might be considered of public
health relevance (either an increase or decrease in
heaviness of smoking equivalent to one cigarette per day
per additional cup of coffee consumed per day, based on
the 95% conﬁdence interval around our point estimate),
but the point estimate was in the opposite direction to that
observed in study 1.
Figure 4 Coffee consumption and smoking heaviness forest plot (cigarettes per day) in UK Biobank. Effect size (ES) estimates reﬂect change in
cigarettes per day per additional cup of coffee consumed per day; CI = conﬁdence interval; SNP = single nucleotide polymorphism [Colour ﬁgure
can be viewed at wileyonlinelibrary.com]
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GENERAL DISCUSSION
Taken together, our results suggest that coffee
consumption is unlikely to have a major causal impact
on cigarette smoking. If it does inﬂuence smoking, this is
not likely to operate via effects of caffeic acid, quercetin or
p-coumaric acid on nicotine metabolism. The
observational association between coffee consumption
and cigarette smoking may be due to smoking impacting
upon coffee consumption, or confounding. It is likely that
at least some of the positive observational association
between coffee consumption and cigarette smoking is due
to the impact of smoking upon coffee intake. There is
evidence from Mendelian randomization analysis, using a
genetic variant that determines heaviness of smoking
[48], that heavier smoking increases coffee consumption
causally [49].
There are some limitations to our approach that
should be considered. First, pleiotropy is a potential
problem in Mendelian randomization analyses. We
therefore performed analyses using all eight SNPs,
but also restricting to the two SNPs that are involved
directly in caffeine metabolism. We also conducted a
sensitivity analysis using the weighted median
function approach, which generates a consistent
estimate of causal effect even when up to 50% of the
information in the analysis comes from SNPs that are
invalid (i.e. pleiotropic). These produced similar
results, suggesting that the results are less likely to
be due to pleiotrophic effects of a single SNP, or that
if pleiotrophy is present, it is not inﬂuencing our
results substantially. Secondly, our Mendelian
randomization may have lacked power to detect small
effects. In the UK Biobank sample, we estimate that
we had between 61 and 89% power to detect an
association of 1.5 cigarettes per day per additional
cup of coffee consumed (based on SDs of 2 and 8.5
for coffee and cigarettes per day, respectively, alpha of
0.05 and the genetic risk score explaining between
0.5 and 1% of variance in coffee consumed). Thirdly,
we used only a limited number of SNPs in our
Mendelian randomization analyses; a polygenic risk
score including a larger number of SNPs might have
provided greater power by capturing more variance
in coffee consumption. Unfortunately, the full results
of the GWAS of coffee consumption that we used are
not publicly available, so we were able to use only
the variants that reached genome-wide signiﬁcance
and were reported. Fourthly, we did not distinguish
between caffeinated and decaffeinated coffee
consumption. The CCGC GWAS phenotype was
‘predominantly regular-type’ of coffee consumption
(which is likely to include some decaffeinated
consumption), although they also ran separate
analyses looking speciﬁcally at decaffeinated coffee
consumption. They found evidence that SNPs near
AHR also increased decaffeinated coffee consumption,
due probably to a continuation of coffee consumption
behaviour in individuals who have switched from
caffeinated to decaffeinated consumption. Given that
the genetic variants are likely to determine both types
of consumption and it is difﬁcult to distinguish
accurately between the two, we do not think that further
stratiﬁcation of these analyses into decaffeinated and
caffeinated consumers is likely to be informative. Fifthly,
in our in-vitro experiments, we did not investigate the
effects of coffee itself. Caffeine has already been tested
and has not been shown to inhibit CYP2A6 activity or
inﬂuence cigarette consumption [25,30]. The compounds
we investigated were all putative inhibitors based on the
literature, their structures and the amounts in coffee
[23]. Kinetic assessments on compound mixtures such
as coffee are possible, but would provide little indication
of the type of inhibition and the duration of action (i.e.
mechanism-based inhibitors may elicit a prolonged
inhibitory effect relative to competitive inhibitors).
What these results highlight is the need to be wary of
potential chance ﬁndings, in particular where statistical
evidence is modest (as in study 1). They also illustrate
the need to triangulate potentially important ﬁndings
with both mechanistic studies that interrogate putative
biological pathways (study 2) and direct replication
studies (study 3), where possible using methods that
support stronger causal inference [50]. Given the
growing concerns that many published biomedical
research ﬁndings may be false [51], and that the
reproducibility of much research is consequently lower
than is desirable [52], we believe that approaches similar
to that we have adopted here will be increasingly
important.
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